Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 4

Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)

University of Virginia · with American Diabetes Association, National Institutes of Health (NIH) · NCT03883412

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 21–60 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 4
Target enrollment
60
US sites recruiting
1
Study start
February 28, 2019
Record last updated
August 12, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and muscle capillary blood volume, improves vascular function in the larger conduit vessels, and enhances insulin's metabolic action in humans with Type 2 diabetes. Subjects will be randomized to one of the three groups: exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 16 weeks of intervention.

Being studied: Exercise; Liraglutide

Conditions: Type2 Diabetes

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Age 21-60
  • A1C ≤ 8.5%
  • Never on GLP-1RA (eg: exenatide, liraglutide) or DPP4I ( eg: Sitaglipton)
  • On stable dose of oral hypoglycemic agents >4 months
  • On stable dose of other medications for >4 months

Exclusion Criteria

  • Taking Insulin
  • Smoking presently or in the past 6 months
  • BP >160/90
  • BMI >35
  • Family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome
  • History of congestive heart failure, ischemic heart disease, severe pulmonary disease, liver or kidney disease.
  • Any vascular disease such as myocardial infarction, stroke, peripheral vascular disease
  • Presence of an intracardiac or intrapulmonary shunt (we will screen for this by auscultation during the physical exam by PI).
  • Pregnant or breastfeeding.
  • Known hypersensitivity to perflutren (contained in Definity)

Recruiting US locations

  • University of Virginia

    Charlottesville, VA 22906

    Site contact: Zhenqi Liu, MD · 434-243-2603 · zl3e@virginia.edu

Study contacts (from the official record)

  • Lee Hartline, MEd · 434-924-5247 · lmh9d@virginia.eud
  • Linda Jahn, RN, MEd · 434-924-1134 · las6e@virginia.edu
All diabetes studies in Virginia →
Effect of Exercise and/or Liraglutide on Vascular Dysfunction and… (NCT03883412) | Bored Studies